Myelophthisis
ICD-10 D61.82 is a billable code used to indicate a diagnosis of myelophthisis.
Myelophthisis refers to the replacement of bone marrow by abnormal tissue, leading to impaired hematopoiesis and resultant blood cell deficiencies. This condition can arise from various causes, including malignancies, infections, and infiltrative diseases such as fibrosis or granulomatous disease. Aplastic anemia, a specific type of myelophthisis, is characterized by the failure of the bone marrow to produce adequate blood cells, resulting in pancytopenia. Patients may present with symptoms of anemia, such as fatigue and pallor, as well as increased susceptibility to infections and bleeding due to thrombocytopenia. The diagnosis of myelophthisis typically involves a combination of clinical evaluation, blood tests, and bone marrow biopsy, which reveals the extent of marrow infiltration and the presence of abnormal cells. Treatment options may include supportive care, immunosuppressive therapy, or hematopoietic stem cell transplantation, depending on the underlying cause and severity of the condition.
Detailed reports of blood tests, bone marrow biopsy findings, and treatment plans.
Diagnosis and management of patients with unexplained anemia or cytopenias.
Ensure accurate documentation of the type of anemia and any associated conditions.
Comprehensive documentation of cancer history, treatment regimens, and response to therapy.
Management of patients with hematologic malignancies leading to myelophthisis.
Document any concurrent treatments that may affect bone marrow function.
Used to evaluate anemia and cytopenias in patients suspected of myelophthisis.
Document the reason for the CBC and any relevant clinical findings.
Hematologists should ensure that the CBC results are interpreted in the context of the patient's overall clinical picture.
Myelophthisis is a condition characterized by the replacement of bone marrow by abnormal tissue, leading to impaired blood cell production and various hematologic disorders.
